Will Ziopharm Ever be Able to Commercialize Their Cell Therapy Products? Continuing Delays for Ziopharm’s TCR-T Programs; TriArm’s Joint Venture Eden BioCell Dissolved; Ziopharm Q3 2021 Earnings Call Summary
On Monday, November 8, Ziopharm held their Q3 2021 earnings call (press release) highlighting that during H1 2022 they anticipate manufacturing therapies at their Houston, TX, clinical production unit (CPU), as well as dosing the first patient in their TCR-T Library program. Moreover, management announced that they have developed four additional TCRs and plan submitting an amended IND protocol within the next few months. Below, Celltelligence provides insights on Ziopharm’s continued program delays and collaboration failures, while discussing the company’s likelihood of successfully bringing a cell therapy product to market.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.